Product Description: Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor[1]. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia [2].
Applications: Cancer-programmed cell death
Formula: C11H19ClN4O3
Citations: Asian J Pharm Sci. 2023 Mar 20./J Colloid Interface Sci. 2024 May:661:908-922./Sci Rep. 2023 Apr 21;13(1):6528./Theranostics. 2022 Apr 4;12(7):3196-3216.
References: [1]Varia MA, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71(2):270-7./[2]Masaki Y, et al. Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent "Pimonidazole" in Hypoxia. PLoS One. 2016 Aug 31;11(8):e0161639./[3]Kristina Y Aguilera, et al. Hypoxia Studies with Pimonidazole in vivo. Bio Protoc/[4]Stephanie M Evans, et al. Molecular probes for imaging of hypoxia in the retina. Bioconjug Chem. . 2014 Nov 19;25(11):2030-7./[5]Stephanie M Evans, et al. Molecular probes for imaging of hypoxia in the retina. Bioconjug Chem. . 2014 Nov 19;25(11):2030-7.
CAS Number: 70132-51-3
Molecular Weight: 290.75
Compound Purity: 99.96
Research Area: Cancer
Solubility: DMSO : 250 mg/mL (ultrasonic)/H2O : 100 mg/mL (ultrasonic)
Target: Others
English
Deutsch
